Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
475.60    5.00 (1.06%)
Bid:
473.20
Ask:
473.80
Spread: 0.60 (0.127%)
Market Cap: £2.45b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

Share Buyback Programme

5 Jun 2025 08:30

RNS Number : 5037L
QinetiQ Group plc
05 June 2025
 

News release

QinetiQ Group plc

Share Buyback Programme

5 June 2025 - QinetiQ Group plc ("QinetiQ" or the "Group") confirms the completion by Numis Securities Limited ("Deutsche Numis") of the third £50 million tranche of its share buyback programme, as announced on 3 February 2025. On 17 March 2025, QinetiQ announced a further extension to its share buyback programme of up to £200m over the following two years (the "Programme").

QinetiQ has today entered into an agreement with Deutsche Numis to execute the first tranche of the £200 million Programme, with a maximum aggregate value of up to £50 million (the "First Tranche"). Under the First Tranche, which is expected to complete by no later than 28 November, Deutsche Numis will make trading decisions independently of QinetiQ in accordance with certain pre-set parameters. The First Tranche will be effected under the authority granted by shareholders at QinetiQ's Annual General Meeting held on 18 July 2024 (the "2024 Authority"), and any subsequent authority granted at QinetiQ's 2025 Annual General Meeting. The maximum remaining number of shares that may be repurchased pursuant to the 2024 Authority is 30,892,966 Ordinary Shares.

Any purchases under the Programme will be carried out on the London Stock Exchange and any other UK recognised investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with the Buyback Authority, Chapter 12 of the UK Financial Conduct Authority's Listing Rules, and Regulation (EU) No 596/2014 and Commission Delegated Regulation (EU) No 2016/1052 (both as they form part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018), including where relevant pursuant to the UK Market Abuse (Amendment) (EU Exit) Regulations 2019.

Any Ordinary Shares purchased pursuant to the Programme will be cancelled, and the number of Ordinary Shares in issue reduced accordingly.

About QinetiQ

QinetiQ is an integrated global defence and security company focused on mission-led innovation. QinetiQ employs circa 8,500 highly-skilled people, committed to creating new ways of protecting what matters most; testing technologies, systems, and processes to make sure they meet operational needs; and enabling customers to deploy new and enhanced capabilities with the assurance they will deliver the performance required.

For further information please contact:

Stephen Lamacraft, Interim Group Investor Relations Director: +44 (0) 7471 885817

Stephanie Mann, Group Head of Media Relations: +44 (0) 7770 720268

James Field, Company Secretary: +44 (0) 7841 662957

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIMRTMTIMBFA
Date   Source Headline
15th Mar 20245:24 pmRNSHolding(s) in Company
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20244:05 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20245:21 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20241:54 pmRNSDirector Declaration
5th Mar 202412:08 pmRNSDirector Declaration
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20244:00 pmRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.